Is dupilumab effective in adult-onset atopic dermatitis: Real-life experience of 16 patients.

Autor: Erbağcı E; Department of Dermatology and Venereology, Uşak University Training and Research Hospital, Uşak, Turkey., Demirel Öğüt N; Department of Dermatology and Venereology, Uşak University Training and Research Hospital, Uşak, Turkey., Koç Yıldırım S; Department of Dermatology and Venereology, Uşak University Training and Research Hospital, Uşak, Turkey., Hapa FA; Department of Dermatology and Venereology, İzmir Demokrasi University Buca Seyfi Demirsoy Training and Research Hospital, İzmir, Turkey.
Jazyk: angličtina
Zdroj: Journal of cosmetic dermatology [J Cosmet Dermatol] 2022 Oct; Vol. 21 (10), pp. 4852-4857. Date of Electronic Publication: 2022 Feb 10.
DOI: 10.1111/jocd.14821
Abstrakt: Background: Dupilumab is approved for the treatment of atopic dermatitis (AD). However, there are few studies demonstrating its efficacy and safety, particularly in the treatment of adult-onset AD.
Objective: The aim of this study is to evaluate the real-life experience regarding the efficacy and safety of dupilumab in the treatment of adult-onset AD.
Methods: This study is a case series in retrospective design. Patients with the diagnosis of adult-onset AD, using dupilumab at a standard dose for at least 3 months, were included in the study. Demographic and laboratory data of the cases, data regarding to dupilumab treatment, were recorded. The eczema area severity index (EASI) and the visual analog scale (VAS) for itch were used to evaluate treatment efficacy.
Results: A total of 16 patients, 6 female and 10 male, were included. The median age was 41 years, the median age of the disease onset was 37.5 years, and the median duration of the disease was 90 months. The median duration of the dupilumab treatment was 10.5 months. The mean percent reduction from baseline in EASI score was 85.8 ± 12.2 at 3 months, 90.7 ± 9.3 at 6 months, and 93.1 ± 5 at 12 months. The mean percent reduction from baseline in VAS itch score was 82.2 ± 8.6 at 3 months. Acute vestibular neuritis was developed in one patient during the dupilumab therapy and resolved with anti-inflammatory therapy.
Conclusion: Dupilumab seems to be highly effective and safe in the treatment of adult-onset AD. The present study is important as it is the first study to evaluate this patient group specifically.
(© 2022 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje